Fig 4.

Anticipated absolute effects for patients with type 2 diabetes and chronic kidney disease, by drug treatment. Figure shows absolute benefits and harms of the drugs for patients with type 2 diabetes and chronic kidney disease. Estimates represent risk differences per 1000 patients in five years compared with standard treatments. Absolute effects were anticipated by applying the relative effects to the baseline risks adopted from a previous guideline panel. Figure is restricted to adults with type 2 diabetes and chronic kidney disease as an example, with the full populations in appendix 6 and the online tool (https://qingys.shinyapps.io/data_visualization) or the MATCH-IT tool (https://matchit.magicevidence.org/230125dist-diabetes). Non-steroidal mineralocorticoid receptor antagonists (MRAs) mainly refer to finerenone. GLP-1=glucagon-like peptide-1; SGLT-2=sodium glucose cotransporter-2